Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trypanosoma brucei | Phosphatidylinositol 3-kinase tor1 | 0.0021 | 0.0271 | 1 |
Trypanosoma brucei | phosphatidylinositol 3-kinase, putative | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Schistosoma mansoni | phosphatidylinositol 3-and 4-kinase | 0.0021 | 0.0271 | 0.5 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Schistosoma mansoni | ataxia telangiectasia mutated (atm)-related | 0.0021 | 0.0271 | 0.5 |
Loa Loa (eye worm) | phosphatidylinositol 3 | 0.0021 | 0.0271 | 1 |
Loa Loa (eye worm) | phosphatidylinositol 3 | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0109 | 0.334 | 1 |
Entamoeba histolytica | FKBP-rapamycin associated protein (FRAP), putative | 0.0021 | 0.0271 | 0.5 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Echinococcus multilocularis | DNA dependent protein kinase catalytic subunit | 0.0299 | 1 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Giardia lamblia | GTOR | 0.0021 | 0.0271 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0105 | 0.32 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Toxoplasma gondii | target of rapamycin (TOR), putative | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Brugia malayi | Phosphatidylinositol 3- and 4-kinase family protein | 0.0021 | 0.0271 | 0.5 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trypanosoma brucei | phosphatidylinositol 4-kinase, putative | 0.0021 | 0.0271 | 1 |
Brugia malayi | Phosphatidylinositol 3- and 4-kinase family protein | 0.0021 | 0.0271 | 0.5 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trypanosoma brucei | target of rapamycin kinase 3, putative | 0.0021 | 0.0271 | 1 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.0021 | 0.0271 | 1 |
Trypanosoma brucei | phosphatidylinositol 3-related kinase, putative | 0.0021 | 0.0271 | 1 |
Entamoeba histolytica | phosphatidylinositol3-kinaseTor2, putative | 0.0021 | 0.0271 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.